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ABSTRACT 
Background: In autosomal dominant polycystic kidney disease(ADPKD), 
hypertension(HTN) is the most prevalent complication and plays an essential role in 
morbidity and progression of chronic kidney disease(CKD). 
Objective: To assess control of HTN following native nephrectomy(Nx) and renal 
transplant recipients  with ADPKD. 
Design, Setting, and Participants: Blood pressure control was studied retrospectively 
in 144 ADPKD patients who underwent renal transplantation between 2003 and 2013.  
Intervention: Renal transplantation alone(n=67) versus renal transplantation with 
concurrent ipsilateral Nx(n=40) versus renal transplantation with concurrent ipsilateral 
Nx and delayed contralateral nephrectomy(n=37) 
Outcome Measurements and Statistical Analysis: The primary outcome was change 
in quantity and defined daily dose(DDD) of antihypertensive medications after renal 
transplantation. Predictors of DDD at 36months were assessed using a multivariable 
linear regression model. 
Results and Limitations: Comparing pre-operative to post-operative medications at 
12, 24, and 36months follow-up, transplantation with concurrent ipsilateral Nx had a 
greater decrease in quantity(-1.2 vs -0.5medications, p=0.008; -1.1 vs -0.3, p=0.007; 
and -1.2 vs -0.4, p=0.03) and DDD(-3.3 vs -1.0, p=0.0008; -2.9 vs -1.0, p=0.006; and -
2.7 vs -0.6, p=0.007) of antihypertensives than transplantation alone, respectively. 
There was a significant decrease in quantity(p=0.0005) and DDD (p=0.009) of 
medications from post-ipsilateral to 12months post-contralateral Nx.  Limitations 
included retrospective design and inability to correlate blood pressure measurements 
with antihypertensive medication changes. 
Conclusion: In ADPKD patients undergoing renal transplantation, concurrent ipsilateral 
native Nx significantly decreases quantity and DDD of antihypertensives. Delayed 
contralateral native Nx decrease these further.  
Patient Summary: We examined blood pressure control following kidney 
transplantation and removal of native kidneys in autosomal dominant polycystic kidney 
disease patients. Patients with one native kidney removed at time of transplantation 
required less blood pressure medications than those who had kidney transplantation 
alone. Patients who had their second native kidney removed at a later surgery required 
even fewer medications to control blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 Autosomal Dominant Polycystic Kidney Disease(ADPKD) is one of the most 
common renal diseases, affecting 1:400 to 1:1000 people. Among its manifestations, 
hypertension(HTN) stands out as the most prevalent complication, and is an essential 
component to the development and progression of both renal disease and morbidity and 
mortality.[1] HTN in ADPKD occurs early, around age 30, and is the initial presentation 
for approximately 30% of patients.[2] In approximately 60% of patients, HTN occurs 
before any impairment of renal function.[3] HTN plays an essential role in morbidity of 
ADPKD, as cardiovascular complications account for the majority of deaths since renal 
replacement therapies have become prevalent.[4, 5] Therefore, it is crucial to 
aggressively control HTN to preserve and improve cardiac and renal function.[6]  
 Once progressive expansion of renal cysts occurs, the massive enlargement of 
the kidneys and simultaneous shrinkage of normal renal parenchyma eventually leads 
to renal failure. There is an inverse relationship of renal function and HTN: as renal 
function declines, the frequency and severity of HTN increases.[7] When end stage 
renal disease (ESRD) occurs in ADPKD, there is also increased risk of other 
cardiovascular events.[8] Renal transplantation(Tx) is the treatment of choice for ESRD. 
Complications after Tx in ADPKD patients are no greater than in the general 
population.[1] However, despite a functioning renal Tx, the voluminous native kidneys 
may exert a sustained hypertensive effect. How to properly manage the native kidneys 
after Tx, and whether or not surgical means are necessary, remains disputed.[9] 
 Few studies have shown how HTN control is affected with surgical intervention 
for native cystic kidneys. Native nephrectomy (Nx) is occasionally performed at time of 
renal Tx in ADPKD for refractory pain caused by the cumbersome cystic kidney(s), but 
has not been well-documented as a potential therapy for HTN. The few studies that 
have examined how Nx affects HTN have been small or only examined blood pressure 
control in the perioperative period; however, these studies have shown some 
improvement from Nx.[9-11] No large study has shown significant improvement or 
resolution of HTN at long-term follow-up for native Nx with renal Tx in the ADPKD 
population. Our goal was to evaluate how blood pressure responds long-term to this 
surgical intervention. Our hypothesis was ipsilateral native Nx at time of renal Tx would 
decrease required antihypertensives to control blood pressure long-term, and that 
delayed contralateral native Nx would further decrease antihypertensive requirement.  
MATERIALS AND METHODS 
Population 
 Our institution’s transplant and billing databases were searched for patients who 
carried a diagnosis of ADPKD and had renal Tx between 2003 and 2013. Patients who 
had Tx alone or Tx with concurrent ipsilateral native Nx were included. Patients were 
excluded if they had bilateral Nx at time of Tx(n=9), had multi-organ transplant(e.g. liver 
and kidney, (n=3), were lost to follow-up(n=14), or were deceased within 4 months of 
Tx(n=4). 144 patients met the inclusion criteria. Institutional review board approval was 
obtained for this study. 
 The primary outcome was change in quantity and defined daily dose of 
antihypertensive medications for patients after renal Tx. Patients not being treated with 
antihypertensive medications at the time of transplantation were excluded from the 
analysis(n=26). Defined daily dose(DDD) is a means of standardizing and analyzing 
drug consumption among patients, and was created by the World Health Organization. 
It is the “assumed average maintenance dose per day for a drug used for its main 
indication in adults.”[12] Since it can differentiate between different doses of the same 
medication, DDD provides better representation of drug requirements compared to 
using the quantity of different medications alone. Patient comorbidities were compared 
at time of Tx using Charlson Comorbidity Index(CCI).[13] Glomerular filtration rate(GFR) 
was obtained as an appraisal of renal function, and was calculated using the 
Modification of Diet in Renal Disease(MDRD) equation.[14] Blood pressure 
measurements were obtained from clinic notes pre-operatively and through 36 months 
follow-up. Native Nx at time of renal Tx was performed by the transplant surgeon by an 
open approach, and the completion native Nx was performed by a urologic surgeon 
using a laparoscopic approach at a mean of 9.8 months post-Tx. Details of the surgical 
procedures have been described previously.[15] The standard immunosuppression 
regimen was early steroid withdrawal(<7 days), and maintenance immunosuppression 
with tacrolimus and mycophenolate. 
Statistical analysis 
 Descriptive analysis was performed for demographic data. Student’s T-test was 
used for continuous variables and Pearson chi-square test for categorical variables. A 
2-tailed analysis was performed in all tests. Comparing antihypertensives between post-
first Nx and post-second Nx was done using a paired Student’s T-test. All other 
analyses were un-paired.  The analysis of variance(ANOVA) test was used for GFR at 
12, 24, and 36-months postoperatively.  Multivariable linear regression was used to 
determine predictors of DDD of antihypertensives at 36 months. Age, CCI, tobacco use, 
and BMI were included in the multivariable analysis a priori as they were identified as 
potential confounders.  Nephrectomy status and gender were included in the 
multivariable analysis due to having a p-value <0.05 on univariable analysis. A priori 
significance was set at p<0.05 for all analyses. All statistical analyses were performed 
using Stata 13.1(Stata Corp. LP, College Station, TX). 
RESULTS 
 Demographic and patient characteristics data can be found in Table 1. At time of 
Tx, there was no difference between renal Tx alone(Group 1) vs renal Tx with native 
Nx(Group 2) in mean age, gender, ethnicity, BMI, percentage of patients with diabetes 
mellitus, percentage of tobacco users, or percentage of patients requiring pre-Tx 
dialysis. Similarly, no difference was found between groups in number of patients who 
carried a diagnosis of HTN at Tx. Mean CCI, international ionized ratio, GFR, and 
albumin were similar between groups at time of Tx. Hemoglobin at time of Tx was 
slightly lower in Group 1(12.2 g/dL) compared to Group 2(12.8 g/dL),(p=0.02). 
A comparison of medication requirements between Groups 1 and 2 can be found 
in Table 2. At time of Tx, quantity of medications was similar between Group 1 and 
Group 2 (2.3 vs 2.6, p=0.23). There was no difference in DDD between Groups 1 and 2 
(3.7 vs 4.4, p=0.27) at time of Tx.  
Results of medication requirements after ipsilateral and delayed contralateral 
nephrectomy can be found in Figures 1 and 2.  At 4 months post-Tx, the mean quantity 
of medications required to control blood pressure was significantly less in Group 2 
compared to Group 1 (1.3 vs 1.9, p=0.001). Similarly, DDD of antihypertensives was 
much lower in Group 2 than Group 1 (1.2 vs 2.7, p<0.0001). Similar to 4 months follow-
up, patients in Group 2 required less quantity of antihypertensives and DDD compared 
to Group 1 at 8, 12, and 24 months follow-up.. At 36 months, while there was a smaller 
quantity and DDD of antihypertensives in Group 2, this was only significant in DDD of 
antihypertensives (p=0.003), not quantity(p=0.16).  
The mean change in quantity as well as mean change in DDD of 
antihypertensives was calculated from time of Tx to 12 and 24 months post-Tx for 
Group 2. These results showed a significant reduction from pre- to post-Tx in quantity 
and DDD of medications at both time intervals(p=0.008 for change in quantity of 
medications at 12 months, p=0.007 at 24 months; p=0.0008 for change in DDD of 
antihypertensives at 12 months, and p=0.006 at 24 months). The association continued 
up to 36 months follow-up(p=0.03 for quantity of medications, p=0.007 for DDD).   
Patients from Group 2 were further subdivided into those who only had single 
ipsilateral native Nx(Group 2a, n=40) and those who went on to have a delayed 
contralateral (staged bilateral) native Nx(Group 2b, n=37). Results for Group 2b can be 
found in Table 3. We compared the antihypertensive requirements from Group 2b 
before and after their second, contralateral Nx. At 12 months follow-up from their 
contralateral Nx, the mean quantity of medications decreased from 1.7 to 1.1(p=0.0005) 
and DDD decreased from 1.4 to 0.8(p=0.009).  
Multivariable predictors of DDD of antihypertensives at 36 months can be found 
in Table 4.  Male gender(β=1.2, p=0.003), ipsilateral Nx(β=-1.6, p=0.004), and bilateral 
(staged) Nx(β=-1.7, p=0.001) were all predictors on multivariable analysis. The 
multivariable linear regression model was statistically significant(p<0.001) with R2=0.27.   
Reason for native Nx was evaluated and can be found in Table 5. The most 
common reason for both first and second native Nx was intractable pain/discomfort. 
Cyst hemorrhage was the second most common reason.  Reason was not specified in 
12(15.6%) patients for the first Nx and 6(16.2%) patients for the second, contralateral 
Nx. 
Mean pre-operative blood pressure was similar(p=0.66) among Group 1 
(131/77), Group 2a (130/79), and Group 2b (134/80). Mean blood pressures remained 
similar(p=0.65) among Groups 1 (129/76), 2a (130/79), and 2b (126/75) at 12 months 
post-operatively. At 24 and 36 months, blood pressures remained similar(p=0.88 and 
0.96) between Groups 1 (135/77 and 127/73), 2a (133/76 and 128/73), and 2b (134/76 
and 127/74), respectively.  
GFR at 12 months was 51 for Group 1, 53.2 for Group 2a, and 60.7 for Group 
2b(p=0.02). GFR at 24 months was 53.2 for Group 1, 53.4 for Group 2a, and 54.6 for 
Group 2b(p=0.94). GFR at 36 months was 53.2 for Group 1, 53.8 for Group 2a, and 
53.4 for Group 2b(p=0.90). 
DISCUSSION 
  Our results show ipsilateral native Nx with concurrent renal Tx decreases 
quantity and DDD of antihypertensive medications as assessed from 4months up to 
36months. In addition, patients who had staged bilateral native Nx had a greater degree 
of decrease in their antihypertensives(Figures 1 and 2). This association persisted on 
multivariable regression analysis(Table 4) with the presence of Nx having the largest 
overall effect on decrease in DDD of antihypertensive requirements, with 
bilateral(staged) Nx having more effect on decrease of DDD than ipsilateral Nx. We did 
find male gender was predictive of greater DDD of antihypertensives on multivariable 
regression analysis, which is consistent with previous studies showing male gender as a 
risk factor for HTN in this population.[8] We found a decrease in quantity and DDD of 
antihypertensives in the group who had renal Tx alone, although this decrease was 
significantly less than that in the Tx/Nx group. 
Studies have shown the general population with ESRD who undergo renal Tx 
typically do not have significant improvement in HTN, but instead frequently(70-90%) 
develop HTN. More importantly, there have been previous studies showing ADPKD 
patients experience HTN post-renal Tx at a similar rate to that of the general population. 
[16, 17] Our findings are novel and contradictory to these other studies that have 
examined this intervention. However, many of these studies in the past have used 
steroid maintenance as part of immunosuppression, which contributes to HTN, unlike 
our patient population who were steroid free.  
  There are, however, a few, very small studies which have examined a similar 
surgical intervention of native Nx at time of renal Tx for ADPKD patients. A study by 
Song et al. showed greater persistence of HTN following Tx alone than with Tx and 
bilateral native Nx. This study had 24 patients in each group and did not specify follow-
up time.[11] Another study also evaluated the effects on HTN of staged native Nx, 
although this operation was after, not at time of, renal Tx in ADPKD patients. Only one 
patient in this study had this specific intervention, but it was reported the patient’s HTN 
improved after unilateral Nx and completely resolved after staged bilateral native 
Nx.[10] Our results support these small studies and to our knowledge are from the 
largest study to show benefit from surgical intervention of native Nx with renal Tx for 
HTN control. 
The control of HTN in ADPKD is crucial, as these patients are at increased risk 
for cardiovascular complications leading to morbidity and mortality. In order to avoid 
such complications, it is recommended ADPKD patients be monitored early and often, 
looking for elevations in blood pressure. The goal for blood pressure ranges from < 
140/90 to <130/80mmHg.[18, 19] Aggressive control is warranted to prevent damage 
and resultant complications. If multi-drug therapy fails to control HTN, other options, 
such as nephrectomy, should be considered. 
Standard reasons for native Nx in ADPKD patients currently include refractory 
pain, recurrent infections, refractory hematuria, inadequate space for renal grafts, and 
dyspnea.[20] Nephrectomies were performed in our patient population for similar 
reasons. Currently, HTN is not a standard indication for Nx at time of Tx because of lack 
of previous data demonstrating its benefit. Future randomized studies should assess the 
benefit of native Nx with renal Tx as a possible treatment for HTN in ADPKD. 
Although we demonstrated a decrease in antihypertensive medications needed 
to control HTN, we cannot conclude with certainty this will lead to decreased 
complications from HTN for our patient population. Better demonstration of decreased 
morbidity/mortality could be achieved by following our patient population farther out and 
comparing cardiovascular complications, such as myocardial infarcts and 
cerebrovascular attacks, between groups.  
There were no differences in clinic-recorded blood pressures during the 36 
month follow-up among groups. Although we expected to see a decrease in actual 
blood pressure to support a decrease in antihypertensives, we do not know exact dates 
of medication changes.  As such, medications may have been changed based on blood 
pressure recordings or side effects that were not available during retrospective review.  
Our study was not without limitations. We examined patients and medications as 
part of a retrospective study, and thus there is risk of confounders and bias. A future 
prospective study could better quantify risk reduction of antihypertensive medications 
and HTN control after native Nx and Tx. By measuring quantity and DDD of 
antihypertensives to assess HTN control in our groups, we indirectly examined the 
control of HTN in our ADPKD patients. To get a truly representative measure of blood 
pressure control, the addition of home monitoring of daily blood pressures by patients 
could give a more accurate representation of control. This would best be done in a 
prospective study. We only examined patients who had ipsilateral Nx at time of Tx. It 
would be of benefit to examine how bilateral native Nx at time of renal Tx affects blood 
pressure control, and to see if results are consistent with those of the staged Nx group, 
or if simultaneous bilateral Nx has a synergistic effect. Safety of the procedure, 
especially when performed by experienced surgeons, has been well-demonstrated by 
previous studies.[15, 20-22] 
CONCLUSIONS 
 Ipsilateral native nephrectomy performed at time of renal transplantation 
significantly reduces the quantity and defined daily dose of antihypertensives needed to 
adequately control hypertension in patients with autosomal dominant polycystic kidney 
disease, and staged contralateral native nephrectomy reduces antihypertensive 
requirement even further. Performing ipsilateral native nephrectomy with renal 
transplantation and delayed contralateral native nephrectomy on this patient population 
with medically-resistant hypertension may provide a surgical means for improved 
hypertension control.  
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Table 1: Demographics and patient characteristics 
  
Group1 
mean (SD) 
Group 2 
mean (SD) 
TOTAL 
mean (SD) p-value 
n 67 77 144   
Age (years) 54.8 (9.4) 52.7 (10.3) 53.7 (9.89) 0.20 
Gender 
   Male, no. (%)                                    
   Female, no. (%) 
 
30 (45) 
37 (55) 
44 (57) 
33 (43) 
74 (51) 
70 (49) 
0.14 
 
Race 
   Caucasian, no. (%)  
   Other, no. (%) 
63 (94) 
4 (6) 
75 (97) 
2 (3) 
138 (96) 
6 (4) 
0.46 
 
Requiring Dialysis Prior to Tx, no. 
(%) 43 (65) 43 (57) 86 (61) 0.34 
CCI prior to Tx 2.2 (0.41) 2.1 (0.29) 2.1 (0.35) 0.21 
DM, no. (%) 2 (3) 4 (5) 6 (4) 0.51 
BMI prior to Tx (kg/m2) 27.9 (4.8) 30.8 (17.4) 29.4 (13.2) 0.20 
Tobacco use, no. (%) 2 (3) 8 (11) 10 (7) 0.09 
GFR at Tx 8.5 (4.6) 7.5 (4.2) 8.0 (4.4) 0.19 
Hgb at Tx (gm/dL) 12.2 (1.8) 12.8 (1.7) 12.5 (1.8) 0.02 
INR at Tx 1.1 (.34) 1.2 (1.0) 1.2 (0.80) 0.51 
Albumin at Tx (gm/dL) 3.7 (0.41) 3.7 (0.52) 3.7 (0.47) 0.81 
HTN, no. (%) 54 (80.6)  64 (83.1) 118 (81.9) 0.70 
no.- number, Nx- Nephrectomy, Tx- Transplantation, BMI- body mass index, GFR- glomerular  
filtration rate, INR- international normalized ratio, HTN- hypertension 
Table 2: Results 
  
Group 1  
mean (SD) 
Group 2 
mean (SD) 
TOTAL 
mean (SD) p-value 
PreTx quantity of meds 2.3 (1.3) 2.6 (1.2) 2.5 (1.2) 0.23 
          Number of patients 54 74 118  
PreTx DDD of meds  3.7 (3.1) 4.4 (3.4) 4.1 (3.3) 0.27 
          Number of patients 51 61 112  
DDD of meds at 4 mo  2.7 (2.1) 1.2 (1.5) 1.9 (2.0) <0.0001 
          Number of patients 54 64 118  
Quantity of meds at 4 mo 1.9 (1.1) 1.3 (1.0) 1.6 (1.1) 0.001 
          Number of patients 54 64 118  
DDD of meds at 8 mo  2.8 (2.2) 1.0 (1.1) 1.9 (2.0) <0.0001 
          Number of patients 54 52 106  
Quantity of meds at 8 mo  1.9 (1.1) 1.3 (0.9) 1.6 (1.0) 0.002 
          Number of patients 54 52 106  
DDD of meds at 12 mo  2.7 (2.3) 1.0 (1.2) 2.0 (2.1) 0.0001 
          Number of patients 54 42 96  
Quantity of meds at 12 mo  1.9 (1.1) 1.3 (0.9) 1.6 (1.1) 0.019 
          Number of patients 54 42 96  
DDD of meds at 24 mo  2.7 (2.2) 1.3 (1.5) 2.1 (2.1) 0.002 
          Number of patients 54 33 87  
Quantity of meds at 24 mo 2.0 (1.2) 1.5 (1.0) 1.8 (1.1) 0.045 
          Number of patients 54 33 87  
DDD of meds at 36 mo  2.9 (2.3) 1.4 (1.4) 2.4 (2.1) 0.003 
          Number of patients 47 26 73  
Quantity of meds at 36 mo  2.0 (1.2) 1.6 (0.9) 1.8 (1.1) 0.16 
          Number of patients 47 26 73  
Change in mean quantity of meds 
from preTx to 12 mo  -0.5 (1.5) -1.2 (1.3) -0.8 (1.4) 0.008 
Change in DDD from preTx to 12 
mo  -1.0 (3.0) -3.3 (3.3) -2.0 (3.3) 0.0008 
Change in mean quantity of meds 
from preTx to 24 mo  -0.3 (1.4) -1.1 (1.1) -0.6 (1.3) 0.007 
Change in DDD from preTx to 24 
mo  -1.0 (2.9) -2.9 (1.7) -1.7 (3.0) 0.006 
Change in mean quantity of meds 
from preTx to 36 mo -0.4 (1.5) -1.2 (1.4) -0.6 (1.5) 0.03 
Change in DDD from preTx to 36 
mo  -0.6 (3.1) -2.7 (2.8) -1.3 (3.1) 0.007 
Tx-transplantation, mo-months, DDD-defined daily dose 
     
 
 
Table 3. Results of Staged Nephrectomy (Group 2b) 
 Group 2b before 
2nd Nx 
Group 2b after 2nd 
Nx 
p-value 
Quantity of meds, 
pre-2nd Nx to 12 mo 
follow-up 
1.7 (0.7) 
before 
1.1 (0.7) 
after 
 
0.0005 
DDD of meds, pre-
2nd Nx to 12 mo 
follow-up 1.4 (1.3) 0.8 (0.9) 
 
 
0.009 
  Nx-Nephrectomy, meds-medications, mo-months, f/u-follow-up, DDD-defined daily 
dose 
 
Table 4. Multivariable predictors of 36-month defined daily dose (DDD) of 
hypertensive medications 
 β p-value      95% Confidence Interval 
Nephrectomy 
  (reference=none) 
    
  Ipsilateral Nx -1.6 0.004 -2.64 -0.53 
  Bilateral Nx -1.7 0.001 -2.70 -0.74 
Gender (male) 1.2 0.003 0.42 2.04 
Age 0.0 0.375 -0.02 0.06 
Tobacco use -0.5 0.523 -2.03 1.04 
CCI 0.2 0.753 -0.99 1.36 
BMI 0.0 0.922 -0.7 0.08 
  CCI- Charlson comorbidity index, BMI-body mass index, Nx-nephrectomy 
 
 
 
Table 5. Reason for Native Nephrectomy 
Reason for Nephrectomy Nephrectomy 1 
no. (%) 
Nephrectomy 2 
no. (%) 
Pain/Discomfort 54 (70) 28 (75.7) 
Dyspnea 1 (1.3) 1 (2.7) 
Early Satiety 2 (2.6) 0 (0) 
Cyst Hemorrhage 6 (7.8) 2 (5.4) 
Recurrent UTI 1 (1.3) 0 (0) 
Rule out RCC 1 (1.3) 0 (0) 
Reason not specified 12 (15.6) 6 (16.2) 
  no.-number, UTI-urinary tract infection, RCC-renal cell carcinoma 
 
 
Figure 1 
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